Roivant Sciences (ROIV) Interest Expenses (2022 - 2024)
Roivant Sciences' (ROIV) quarterly Interest Expenses came in at $1.6 billion in Q1 2026, up 127.74% YoY from $701.2 million in Q1 2025, and up 2419495.45% on a QoQ basis from $66000.0 in Q3 2025.
Analysis
Roivant Sciences (ROIV) Interest Expenses (2022 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 7 years of Interest Expenses data on file, last reported at $1.6 billion in Q1 2026.
- Quarterly Interest Expenses rose 127.74% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 127.74% YoY) and the FY2026 annual result came in at $1.6 billion, up 127.74% from the prior year.
- Interest Expenses improved to $1.6 billion in Q1 2026, from $66000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $1.6 billion in Q1 2026 to a low of $66000.0 in Q3 2025.
- A 5-year average of $171.3 million and a median of $15.6 million in 2022 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 5965.38% in 2025, down 99.94% in 2025.
- Tracing ROIV's Interest Expenses over 5 years: stood at $19.4 million in 2022, then jumped by 42.33% to $27.6 million in 2023, then surged by 310.1% to $113.2 million in 2024, then tumbled by 99.94% to $66000.0 in 2025, then soared by 2419495.45% to $1.6 billion in 2026.
- The last three Interest Expenses figures came in at $1.6 billion (Q1 2026), $66000.0 (Q3 2025), and $184000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Roivant Sciences | 24.96 Bn | 24.96 Bn | 1.16 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 13.40 Mn |
| Dec 31, 2023 | 27.60 Mn |
| Sep 30, 2023 | 9.25 Mn |
| Jun 30, 2023 | 8.91 Mn |
| Dec 31, 2022 | 19.39 Mn |
| Sep 30, 2022 | 8.34 Mn |
| Jun 30, 2022 | 2.61 Mn |